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PRELIMINARY FINDINGS 
 Preliminary results from the qualitative analysis of clinician interviews have identified a number of  factors as 
influential on the decision to offer thrombolysis to patients with acute ischaemic stroke (Figure 2): 
 
Fig. 2 Influential factors in decision-making regarding thrombolysis for acute stroke 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 These factors will be combined with those identified in the secondary literature.  
 A structured ranking exercise with clinicians will be used to prioritise patient factors for inclusion in the patient 
vignettes in the DCE, which will include CT scans to enhance clinical realism and ensure the external validity 
of related decisions is maximised. 
 Next steps will include design and piloting of an online DCE. 
           
BENEFITS OF THE DCE APPROACH 
 The DCE approach offers a means to explore and quantify the implicit trade-offs made between competing 
factors within a thrombolysis decision-making scenario. 
 The study findings will be used to inform strategies to reduce unwarranted variation in thrombolysis rates, with 
tangible benefits in terms of improved stroke patient care and likely costs savings associated with optimal use. 
 Informing regional CPD learning programmes (e.g. NHS Stroke Improvement Programme). 
 Supporting implementation of a computerised decision aid for stroke thrombolysis (COMPASS). 
 Informing clinical audit and evaluation (e.g., SSNAP). 
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Understanding Clinicians’ Decisions to offer Intravenous Thrombolysis to  
Patients with Acute Ischaemic Stroke: A Discrete Choice Experiment 
INTRODUCTION 
 Intravenous thrombolysis is the most effective emergency treatment for acute ischaemic stroke. Despite 
considerable evidence for thrombolysis use in well-defined patient groups within 4.5 hours of symptom onset [1, 
2], there is variation in treatment rates across the UK [3].  
 Availability of services (such as rapid access to CT scanning) initially accounted for much variation in thrombolytic 
treatment rates between centres; although with the wide implementation of 24/7 hyperacute stroke services, this 
is no longer the case.  Continuing variation between centres may reflect variations in clinical decision-making on 
who should be offered thrombolysis. 
 
OBJECTIVES 
(i) to determine which patient factors influence clinical decision making about the offer of thrombolysis; 
(ii) to identify and quantify the trade-offs clinicians make regarding the decision to offer thrombolysis; 
(iii) to determine which clinician factors influence clinical decision making about the offer of thrombolysis; 
(iv) to influence clinicians’ behaviour by translating learning into CPD activity, national clinical guidelines, and  
      informing clinical audit and evaluation programmes. 
 
By understanding how different clinicians make often difficult trade-offs between risks and benefits in their decision-
making for different patients, we can better understand how we can target optimal use of thrombolysis. 
 
METHODS 
 A discrete choice experiment (DCE) using patient vignettes will be conducted to understand which factors are 
important to the deliberations that clinicians make when considering offering thrombolysis to patients.  The seven 
stages of the research are shown in Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 To identify the full range of factors that influence decision making about thrombolysis we: (i) extracted factors from 
secondary sources (systematic reviews/meta-analyses and previous qualitative work we conducted for the DASH 
programme exploring factors involved with decision making about thrombolysis); and (ii) conducted semi-
structured interviews with clinicians (different levels of experience with thrombolysis) to elicit their beliefs and 
experiences regarding important and influential factors regarding the decision to offer thrombolysis. 
 
A De Brún1, D Flynn1, L Ternent1, E Lancsar2, C Price3, H Rodgers4, GA Ford4,5, RG Thomson1  
1 Institute of Health and Society, Newcastle University, UK 2 Centre for Health Economics, Monash University, Australia 3 Northumbria Healthcare NHS Trust, Ashington, UK   
4 Institute for Ageing and Health (Stroke Research Group), Newcastle University 5 Newcastle upon Tyne Hospital NHS Foundation Trust 
Disclaimer: This poster presents independent research commissioned by the National Institute for Health Research (NIHR) Health Services and Delivery Research (12/5001/45). The views expressed in this poster are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. 
Fig. 1 Stages of the Research 
 
Clinical patient factors 
• Blood pressure 
 
• Blood glucose 
 
• INR level (if on Warfarin) 
 
• Age of patient 
 
• Medical history (e.g. 
recent operation, previous 
stroke) 
 
• Stroke severity (NIHSS) 
Non-medical patient 
factors 
• Patient pre-stroke 
cognitive/ dependency 
status 
 
• Patient frailty 
 
• Patient/family preferences 
and values about 
treatment 
Clinician factors 
• Experience level 
 
• Attitude towards risk and 
uncertainty 
 
• Medical speciality 
 
• Perception of efficacy of 
thrombolysis 
 
• Adherence to licencing 
criteria/local guidelines 
